Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus seed implantation for radioactive iodine-refractory differentiated thyroid cancer
ChiCTR2100054556Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in well-differentiated thyroid cancer (WDTC), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-free survival. Started Jun 2021; status: recruiting.
02
Drugs
surufatinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR2100054556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054556.